CLAIMS

1. A pharmaceutical composition which comprises a pharmaceutically acceptable carrier or diluent and:

(a) an inhibitor of the RSV fusion protein; and

(b) a benzodiazepine derivative capable of inhibiting RSV replication.

2. A composition according to claim 1, wherein component (b) is a compound of formula (V), or a pharmaceutically acceptable salt thereof,



(V)

wherein:

- R^1 represents C_{1-6} alkyl, aryl or heteroaryl;
- R^2 represents hydrogen or C_{1-6} alkyl;
- each R^3 is the same or different and represents halogen, hydroxy, C_{1-6} alkyl, C_{1-6} alkoxy, C_{1-6} alkylthio, C_{1-6} haloalkyl, C_{1-6} haloalkoxy, amino, mono(C_{1-6} alkyl)amino, di(C_{1-6} alkyl)amino, nitro, cyano, $-CO_2R'$, $-CONR'R''$, $-NH-CO-R'$, $-S(O)R'$, $-S(O)_2R'$, $-NH-S(O)_2R'$, $-S(O)NR'R''$ or $-S(O)_2NR'R''$, wherein each R' and R'' is the same or different and represents hydrogen or C_{1-6} alkyl;
- n is from 0 to 3;
- R^4 represents hydrogen or C_{1-6} alkyl;
- X represents -CO-, $-CO-NR'-$, -S(O)- or $-S(O)_2-$, wherein R' is hydrogen or a C_1-C_6 alkyl group; and
- R^5 represents an aryl, heteroaryl or heterocyclyl group which is substituted by a C_1-C_6 hydroxyalkyl group or a $-(C_1$-C_4 alkyl)-X_1-(C_1-C_4 alkyl)-X_2-(C_1-C_4 alkyl) group, wherein

X_1 represents -O-, -S- or -NR'-, wherein R' represents H or a C_1-C_4 alkyl group and X_2 represents -CO-, -SO- or -SO_2-, or R_5 represents -A_1-Y-A_2, wherein:

- A_1 is an aryl, heteroaryl, carbocyclyl or heterocyclyl group;
- Y represents a direct bond or a C_1-C_4 alkylene, -SO_2-, -CO-, -O-, -S- or -NR'- moiety, wherein R' is a C_1-C_6 alkyl group; and
- A_2 is an aryl, heteroaryl, carbocyclyl or heterocyclyl group.

3. A composition according to claim 2 wherein wherein R^1 is C_{1-2} alkyl or phenyl.

4. A composition according to either claim 2 or claim 3, wherein wherein R^2 is hydrogen

5. A composition according to any one of claims 2 to 4 wherein R^3 is halogen, hydroxy, C_{1-4} alkyl, C_{1-4} alkoxy, C_{1-4} alkylthio, C_{1-4} haloalkyl, C_{1-4} haloalkoxy, amino, mono(C_{1-4} alkyl)amino or di(C_{1-4} alkyl)amino.

6. A composition according to claim 5 wherein R^3 is fluorine, chlorine, bromine, C_{1-2} alkyl, C_{1-2} alkoxy, C_{1-2} alkylthio, C_{1-2} haloalkyl, C_{1-2} haloalkoxy, amino, mono(C_{1-2} alkyl)amino or di (C_{1-2} alkyl)amino.

7. A composition according to any of claims 2-6, wherein R^4 is hydrogen or C_{1-2} alkyl.

8. A composition according to any one of claims 2-7, wherein X is -CO- or -CO-NR'- wherein R' represents hydrogen or a C_1-C_2 alkyl group.

9. A composition according to any one of claims 2-8, wherein R^5 is a 5- or 6- membered heterocyclyl, aryl or heteroaryl ring which is substituted by a C_1-C_6 hydroxyalkyl group or a -(C_1-C_4 alkyl)-X_1-(C_1-C_4 alkyl)-X_2-(C_1-C_4 alkyl) group, wherein X_1 and X_2 are as defined in claim 2.

10. A composition according to claim 9, wherein R^5 is a 5- or 6- membered heteroaryl group which is substituted by a $-CH_2-OH$ or $-(C_1-C_4$ alkyl$)-NR'-(C_1-C_4$ alkyl$)-S(O)_2-(C_1-C_4$ alkyl) substituent, wherein R' is hydrogen or C_1-C_2 alkyl.

11. A composition according to claims 2-10, wherein A_1 is an aryl or heteroaryl group.

12. A composition according to claim 11, wherein A_1 is a phenyl group, a monocyclic 5- or 6- membered heteroaryl group or a 5- to 6- membered heteroaryl group fused to a monocyclic oxo-substituted 5- to 6- membered heterocyclyl group.

13. A composition according to claims 2-12 wherein A_1 is unsubstituted or substituted by 1 or 2 substituents selected from halogen, cyano, nitro, C_1-C_4 alkyl, C_1-C_4 haloalkyl and C_1-C_4 alkoxy substituents.

14. A composition according to claims 2-13, wherein Y represents a direct bond, a C_1-C_2 alkylene group, $-SO_2-$ or -O-.

15. A composition according to claims 2-14 wherein A_2 is a phenyl, 5- to 6- membered heteroaryl, 5- to 6- membered heterocyclyl or C_3-C_6 cycloalkyl group.

16. A composition according to claims 2-15, wherein when A_2 is a heterocyclyl group it is attached to the moiety Y via a N atom.

17. A composition according to claims 2-16, wherein A_2 is unsubstituted or is substituted by 1 or 2 substituents which are selected from C_1-C_4 alkyl and halogen substituents when A_2 is a heteroaryl or aryl group and which are selected from C_1-C_4 alkyl, halogen and oxo substituents when A_2 is a carbocyclic or heterocyclyl group.

18. A composition according to claims 2-17, wherein A_2 is a piperazinyl, pyridyl, morpholinyl, pyrrolidinyl, piperidinyl, pyrazinyl, cyclopropyl, phenyl or S,S-dioxo-thiomorpholino group, which is unsubstituted or substituted by a C_1-C_2 alkyl group.

19. A composition according to any one of claims 2-18 wherein the benzodiazepine derivative of formula (V) is a benzodiazepine derivative of formula (Va):



(Va)

wherein:

- X is -CO- or -CO-NH-; and
- R^5 is a 5- to 6- membered heteroaryl group, for example a furanyl group, which is substituted by $-CH_2-OH$ or $-(C_1-C_4$ alkyl$)-N(CH_3)-(C_1-C_4$ alkyl$)-SO_2-(C_1-C_4$ alkyl) or R_5 represents $-A_1-Y-A_2$, wherein:
- A_1 is a phenyl, pyridyl, furanyl, thiazolyl, oxazolyl, isoxazolyl, thienyl or 1H-imidazo[4,5-b]pyridin-2-(3H)-one moiety, which is unsubstituted or substituted by 1 or 2 substituents selected from halogen, cyano, C_1-C_2 alkyl, C_1-C_2 haloalkyl and C_1-C_2 alkoxy substituents;
- Y is a direct bond, a C_1-C_2 alkylene group, $-SO_2-$ or -O-; and
- A_2 is a piperazinyl, pyridyl, morpholinyl, pyrrolidinyl, piperidinyl, pyrazinyl, cyclopropyl, phenyl or S,S-dioxo-thiomorpholino group, which is unsubstituted or substituted by a C_1-C_2 alkyl group.

20. A composition according to claim 1, wherein the benzodiazepine derivative of formula (V) is:
6-(4-Methyl-piperazin-1-yl)-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4] diazepin-3-yl)-nicotinamide;
3,4,5,6-Tetrahydro-2H-[1,2']bipyridinyl-5'-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-amide;

(S)-2-(1,1-Dioxo-1λ6-thiomorpholin-4-yl)-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl-benzamide;

(S)-2-Chloro-4-morpholin-4-yl-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4] diazepin-3-yl)-benzamide;

(S)-2-(1,1-Dioxo-1λ6-thiomorpholin-4-yl)-4-fluoro-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl-benzamide;

(S)-5-Chloro-2-(1,1-dioxo-1λ6-thiomorpholin-4-yl)-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-benzamide;

(S)-2-(1,1-Dioxo-1λ6-thiomorpholin-4-yl)-5-fluoro-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-benzamide;

(S)-5-(4-Methyl-piperazin-1-ylmethyl)-furan-2-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-amide;

(S)-5-Pyrrolidin-1-ylmethyl-furan-2-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-amide;

(S)-5-Piperidin-1-ylmethyl-furan-2-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-amide;

(S)-5-Dimethylaminomethyl-furan-2-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-amide;

(S)-4-Fluoro-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-2-piperidin-1-yl-benzamide;

(S)-4-Fluoro-2-morpholino-4-yl-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4] diazepin-3-yl)-benzamide;

(S)-4-Cyano-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-2-pyrrolidin-1-yl-benzamide;

(S)-4-Cyano-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-piperidine-1-yl-benzamide;

(S)-N-(2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-2-pyrrolidin-1-yl-4-trifluoromethyl-benzamide;

(S)-N-(2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-2-piperidin-1-yl-4-trifluoromethyl-benzamide;

(S)-2-Morpholin-4-yl-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-4-trifluoromethyl-benzamide;

(S)-N-(2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-2-pyrrolidin-1-yl-5-trifluoromethyl-benzamide;

(S)-2-Morpholin-4-yl-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-5-trifluoromethyl-benzamide;

(S)-2-Morpholin-4-yl-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-nicotinamide;

(S)-2-(1,1-Dioxo-1λ6-thiomorpholin-4-yl)-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-nicotinamide;

(S)-2-(1,1-Dioxo-1λ6-thiomorpholin-4-yl)-2-methyl-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-benzamide;

(S)-2-(1,1-Dioxo-1λ6-thiomorpholin-4-yl)-4-methyl-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-benzamide;

(S)-2-(1,1-Dioxo-1λ6-thiomorpholin-4-yl)-6-methyl-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-benzamide;

(S)-2-Chloro-6-(1,1-dioxo-1λ6-thiomorpholin-4-yl)-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-benzamide;

(S)-3-Cyclopropyl-2-oxo-2,3-dihydro-imidazo[4,5-b]pyridine-1-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-amide;

(S)-3-(4-Methyl-piperazine-1-sulfonyl)-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-benzamide;

(S)-4-(4-Methyl-piperazin-1-yl)-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4] diazepin-3-yl)-benzamide;

(S)-N-(2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-3-(piperidine-1-sulfonyl)-benzamide;

(S)-3-(Morpholine-4-sulfonyl)-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4] diazepin-3-yl)-benzamide;

(S)-5-Morpholin-4-ylmethyl-furan-2-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-amide;

(S)-5-Hydroxymethyl-furan-2-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-amide;

(S)-5-(1,1-Dioxo-1λ6-thiomorpholin-4-ylmethyl)-furan-2-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-amide;

(S)-2-Chloro-4-(1,1-dioxo-1λ6-thiomorpholin-4-yl)-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-benzamide;

(S)-2-Chloro-5-(1,1-dioxo-1λ6-thiomorpholin-4-yl)-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-benzamide;

(S)-5-{[(2-Methanesulfonyl-ethyl)-methyl-amino]-methyl}-furan-2-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl-amide;

(S)-2-Pyridin-3-yl-thiazole-4-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-amide;

(S)-2-Pyridin-4-yl-thiazole-4-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-amide;

(S)-4-Methyl-2-pyrazin-2-yl-thiazole-5-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-amide;

(S)-2-Morpholin-4-ylmethyl-furan-3-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-amide;

(S)-3-Morpholin-4-ylmethyl-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-benzamide;

(S)-5-Morpholin-4-ylmethyl-isoxazole-3-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-amide;

(S)-3-Morpholin-4-ylmethyl-furan-2-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-amide;

(S)-5-Pyridin-2-yl-thiophene-2-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-amide;

(S)-2-Methyl-4-(morpholin-4-sulfonyl)-furan-3-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-amide;

(S)-6-Morpholin-4-yl-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-nicotinamide;

(S)-3-Morpholin-4-ylmethyl-thiophene-2-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-amide;
(S)-5-Morpholin-4-ylmethyl-thiophene-2-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-amide;
2-Morpholin-4-yl-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-benzamide;
(S)-5-Phenyl-oxazole-4 carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-amide;
1-(2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-3-(4-phenoxy-phenyl)-urea
an N-oxide of any of the above compounds;
or a pharmaceutically acceptable salt thereof.

21. A composition according to claim 1, wherein the benzodiazepine derivative of formula (V) is (S)-5-(1,1-Dioxo-1λ6-thiomorpholin-4-ylmethyl)-furan-2-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-amide or (S)-2-Chloro-4-morpholin-4-yl-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-benzamide or a pharmaceutically acceptable salt thereof.

22. A composition according to claim 21, wherein the benzodiazepine derivative of formula (V) is (S)-5-(1,1-Dioxo-1λ6-thiomorpholin-4-ylmethyl)-furan-2-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-amide or a pharmaceutically acceptable salt thereof.

23. A composition according to any one of the preceding claims wherein component (a) is a compound of formula (I), or a pharmaceutically acceptable salt thereof,



(I)

wherein:

- X is H or C_{1-6} alkyl; said C_{1-6} alkyl being optionally substituted with halogen, $OCOR_4$ or S(O)n-C_{1-6} alkyl;
- Y is R_4, NR_4R_5, $NCOR_4$, =N-OR_4, -$CONHR_4$, $COOR_4$, -OR_4, aryl, heteroaryl, cyclyl or heterocyclyl, where R4 and R5 are H or C_{1-6} alkyl;
- Z is CR_6R_7, where R_6 and R_7 are independently H, or straight, branched or cyclic C_{1-6} alkyl;
- n is 1-6;
- R_1 is $CONR_4R_5$, CO_2R_4 or C_{1-6} alkyl, said C_{1-6} alkyl can be optionally substituted with OR_4 or NR_8R_9;
- R_8 and R_9 are each independently H, C_{1-6} alkyl, SO_2R_5, CO_2R_4 or COR_4;
- R_2 is selected from the group consisting of NH_2, $CONR_6R_7$, heteroaryl, C_{2-6} alkenyl, CO_2R_4, $N=CPh_2$, $C(=NH)NH_2$ and C_{1-6} alkyl; said alkyl optionally substituted with a member selected from the group consisting of halogen, CN, $NR_{10}R_{11}$, OSO2R_4 and OR_4;
- R_9 and R_{10} are each independently selected from the group consisting of H, C_{1-6} alkyl, C_{3-6} cycloalkyl, CO_2R_4, COR_4 and SO_2R_4;
- R_3 is selected from the group consisting of (1) CO_2R_9; (2) C_{1-6} alkyl optionally substituted with CN, OR_4 or NR_6R_7; and (3) C_{2-6} alkenyl substituted with CN;
- Q is a member selected from the group consisting of



A is C or N, optionally substituted with H, halogen, straight, branched or cyclic C_{1-6} alkyl, C2-6 alkenyl, CO_2R_4, aryl or C_{3-6} cycloalkyl. Where A is carbon, it may also be optionally substituted by O or S via a double bond;

B is C or N; where B is C it may be optionally substituted by H, C_{1-6} alkyl, NO_2, CN, halogen, COR_4, $COOR_4$, $CONHR_4C(=NH)NH_2$ or $C(=NOH)NH_2$.

24. A composition according to claim 23 wherein component (a) is a compound of general formula (I), as defined above, or a pharmaceutically acceptable salt thereof, wherein at least two of R_1, R_2 and R_3 are hydrogen, and the other is hydrogen or $-C(NH)-NH_2$ and/or -X-Y is H, or X is a C_1-C_6 alkylene group which is unsubstituted or substituted by a hydroxy group and Y is H, OH, CN, $-NR'R''$, $-COR'$, $-SO_2R'$ or phenyl, wherein R' and R'' are the same or different and represent a C_1-C_4 alkyl group and/or Z is $-CH_2-$ and/or Q is a moiety



wherein B is -CH- or -N-, A_1 is -C(O)- or -NH- and A_2 is $-CH_2-$, $-CHR'-$ or $-NR''-$, wherein R' is a halogen atom and R'' represents a hydrogen atom or a C_1-C_4 alkyl, C_2-C_4 alkenyl, C_3-C_6 cycloalkyl, $-SO_2-(C_1-C_6$ alkyl), $-SO_2-N(C_1-C_6$ alkyl$)_2$ or $-(CO-NH)_a-(C_1-C_4$ alkyl)-phenyl group, wherein a is 0 or 1, which group is unsubstituted or is substituted with a hydroxy or cyano substituent.

25. A composition according to claims 1 to 22 wherein component (a) is a compound of formula (II), or a pharmaceutically acceptable salt thereof,



(II)

wherein:

- L_1 is $-CH_2-$ or $-CHR_2-CO-$
- each X is the same or different and CH or N;
- each R_1 is the same or different and is C_{1-6} alkyl, halogen, hydroxy, phenyl or $(CH_2)_m=NH_2$;
- n is 1 or 2;
- R_2 is C_{1-6} alkoxy or C_{1-6}alkoxy-phenyl;
- R_3 is C_{1-6}alkyl;
- L_2 is $-CH_2-$ or -NH-;
- Y is C_{1-6} alkyl or C_{1-6} alkenyl;
- Z is H, $N(R_4)_2$, $-C(=O)-R_5$, $-C(=CH_2)-R_5$, $-CH(OH)-R_5$, $-CH(CH3)-R_5$, $-CH(OCH3)-R_5$;
- each R_4 is the same or different and is H, C_{1-6} alkyl;
- R_5 is C_{1-6} alkyl-carbonyl, amino, hydroxyl, aryl, heteroaryl, carbocyclyl, heterocyclyl; and
- m=1-6

26. A composition according to anyone of claims 1 to 22, wherein component (a) is:

1-Cyclopropyl-3-[1-(4-hydroxy-butyl)-1H-benzoimidazol-2-ylmethyl]-1,3-dihydro-imidazo[4,5-c]pyridin-2-one

{2-[2-(1,2-Dihydro-benzotriazol-1-ylmethyl)-benzoimidazol-1-yl]]ethyl}-diethyl-amine

{2-[2-(3-Iodo-2,3-dihydro-indazol-1-ylmethyl)-benzimidazol-1-yl]-ethyl}-dimethyl-amine

1-Isopropenyl-3-[1-(3-methyl-butyl)-1H-benzoimidazol-2-ylmethyl]-1,3-dihydro-benzoimidazol-2-one

1-(4-Hydroxy-benzyl)-3-[1-(3-methyl-butyl)-1H-benzoimidazol-2-ylmethyl]-1,3-dihydro-benzoimidazol-2-one

1-Isopropenyl-3-[1-(3-oxo-butyl)-1H-benzoimidazol-2-ylmethyl]-1,3-dihydro-benzoimidazol-2-one

1-Ethyl-3-[1-(2-hydroxy-2-phenyl-ethyl)-1H-benzoimidazol-2-ylmethyl]-1,3-dihydro-benzoimidazol-2-one

1-Ethyl-3-[1-(4-hydroxy-butyl)-1H-benzoimidazol-2-ylmethyl]-1,3-dihydro-benzoimidazol-2-one

7-[2-(3-Isopropenyl-2-oxo-2,3-dihydrobenzoimidazol-1-ylmethyl)-benzoimidazol-1-yl]-heptanenitril

5-{3-[1-(3-Methanesulfonyl-propyl)-1H-benzoimidazol-2-ylmethyl]-2-oxo-2,3-dihydro-benzoimidazol-1-yl}-pentanenitrile

3-[1-(3-Methyl-butyl)-1H-benzoimidazol-2-ylmethyl]-2-oxo-2,3-dihydro-benzoimidazol-1-carboxylic acid benzylamide

1-Methanesulfonyl-3-[1-(3-methyl-butyl)-1H-benzoimidazol-2-ylmethyl]-1,3-dihydro-benzoimidazol-2-one

3-[1-(3-Methyl-butyl)-1H-benzoimidazol-2-ylmethyl]-2-oxo-2,3-dihydro-benzoimidazol-1-sulfonic acid dimethylamide

1-Isopropenyl-3-(1-propyl-1H-benzoimidazol-2-ylmethyl)-1,3-dihydro-imidazo[4,5-c]pyridine-2-one

Bis(5-amidino-2-benzimidazolyl)-methane

2-{2-[1-[1-(2-Amino-ethyl)-piperidin-4-ylamino]-4-methyl-benzoimidazol-1-ylmethyl}-6-methyl-pyridin-3-ol

or a pharmaceutically acceptable salt thereof.

27. A composition according to any one of claims 1 to 22, wherein component (a) is 1-cyclopropyl-3-[1-(4-hydroxy-butyl)-1H-benzoimidazol-2-ylmethyl]-1,3-dihydro-imidazo[4,5-c]pyridin-2-one, {2-[2-(1,2-dihydro-benzotriazol-1-ylmethyl)-benzoimidazol-1-yl]]ethyl}-diethyl-amine, {2-[2-(3-iodo-2,3-dihydro-indazol-1-ylmethyl)-benzimidazol-1-yl]-ethyl}-dimethyl-amine or a pharmaceutically acceptable salt thereof.

28. A composition according to any one of claims 1 to 22, wherein component (a) is 1-cyclopropyl-3-[1-(4-hydroxy-butyl)-1H-benzoimidazol-2-ylmethyl]-1,3-dihydro-imidazo[4,5-c]pyridin-2-one or 1-Isopropenyl-3-(1-propyl-1H-benzoimidazol-2-ylmethyl)-1,3-dihydro-imidazo[4,5-c]pyridine-2-one or a pharmaceutically acceptable salt thereof.

29. A composition according to any one of the preceding claims wherein component (a) is present in an amount of from 0.025 wt% to 10 wt%.

30. A composition according to any one of the preceding claims wherein component (b) is present in an amount of 0.025 wt% to 10 wt%.

31. A composition according to any one of the preceding claims, for use in the treatment of the human or animal body.

32. Use of:

(a) an RSV fusion protein inhibitor as defined in any one of claims 1 and 23 to 28; and

(b) a benzodiazepine derivative defined in any one of claims 1 to 22,

in the manufacture of a medicament for use in treating or preventing an RSV infection.

33. Use according to claim 32, wherein the medicament is a composition as defined in claim 29 or 30.

34. A product comprising:

(a) an RSV fusion protein inhibitor as defined in any one of claims 1 and 23 to 28; and

(b) a benzodiazepine derivative as defined in any one of claims 1 to 22;

for separate, simultaneous or sequential use in the treatment of the human or animal body.

35. A product according to claim 34 for separate, simultaneous or sequential use in treating or preventing an RSV infection.

36. A method of treating or preventing an RSV infection in a patient, which method comprises the administration to said patient of:

(a) an RSV fusion protein inhibitor as defined in any one of claims 1 and 23 to 28; and

(b) a benzodiazepine derivative as defined in any one of claims 1 to 22.

37. Use of an RSV fusion protein inhibitor as defined in any one of claims 1 and 23 to 28, in the manufacture of a medicament for use in treating or preventing an RSV infection, by co-administration with a benzodiazepine derivative as defined in any one of claims 1 to 22.

38. Use of a benzodiazepine derivative as defined in any one of claims 1 to 22, in the manufacture of a medicament for use in treating or preventing an RSV infection, by co-administration with an RSV fusion protein inhibitor as defined in any one of claims 1 and 23 to 28.